Chemotherapy of Schizophrenia

  • Leo E. Hollister
Part of the Advances in Behavioral Biology book series (ABBI, volume 1)


Few illnesses compare with schizophrenia in the toll they take of the most useful years of an individual’s life. Few illnesses have been so frustrating to explain or treat. Few illnesses create such sadness and guilt in those who cannot find ways to help their affected loved one. “Cures” are rare indeed; probably less than fifteen percent of individuals seriously affected who require any kind of prolonged hospitalization ever again function “normally.” Schizophrenia and alcoholism are the two major problems in psychiatry; they deserve far more attention than they have been given.


Antipsychotic Drug Schizophrenic Patient Collaborative Study Group Phenothiazine Derivative Extrapyramidal Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adelson, D., and Epstein, L. J. 1962. A study of phenothiazines with male and female chronically ill schizophrenic patients. J. Nerv. Ment. Dis. 134:543.PubMedCrossRefGoogle Scholar
  2. Caffey, E. M., Jr.; Diamond, L. S.; Frank, T. V.; Grasberger, J. C.; Herman, L.; Klett, C. J.; and Rothstein, C. 1964. Discontinuation or reduction of chemotherapy in chronic schizophrenics. J. Chronic Dis. 17:347.PubMedCrossRefGoogle Scholar
  3. Casey, J. F.; Bennett, I. F.; Lindley, C. J.; Hollister, L. E.; Gordon, M. H.; and Springer, N. N. 1960a. Drug therapy in schizophrenia: a controlled study of the relative effectiveness of chlor-promazine, promazine, phenobarbital, and placebo. Arch. Gen. Psychiat. 2:210.CrossRefGoogle Scholar
  4. Casey, J. F.; Lasky, J. J.; Klett, C. J.; and Hollister, L. E. 1960b. Treatment of schizophrenic reactions with phenothiazine derivatives: a comparative study of chlorpromazine, trifluproma-zine, mepazine, prochlorperazine, Perphenazine, and phenobarbital. Amer. J. Psychiat. 117:97.PubMedGoogle Scholar
  5. Casey, J. F.; Hollister, L. E.; Lasky, J. J.; Klett, C. J.; and Caffey, E. M. 1961. Combined drug therapy of chronic schizophrenics: a controlled evaluation of placebo, dextroamphetamine, imipramine, isocarboxazid, and trifluoperazine added to maintenance doses of chlorpromazine. Amer. J. Psychiat. 117:997.PubMedGoogle Scholar
  6. Curry, S. H. 1970. Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proc. Roy. Soc. Med. in press.Google Scholar
  7. Engelhardt, D. M.; Rosen, B.; Freedman, N.; and Margolis, R. 1967. Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization — a re-evaluation. Arch. Gen. Psychiat. 16:98.PubMedCrossRefGoogle Scholar
  8. Galbrecht, C. R., and Klett, C. J. 1968. Predicting response to phenothiazines: the right drug for the right patient. J. Nerv. Ment. Dis. 147:173.PubMedCrossRefGoogle Scholar
  9. Goldberg, S. C. 1968. Prediction of response to anti-psychotic drugs. In Psychopharmacology. A Review of Progress 1957-1967. D. Efron (ed.). Washington, D. C.: U. S. Govt. Printing Office, p. 1101.Google Scholar
  10. Gorham, D. R., and Pokorny, A. D. 1964. Effects of a phenothiazine and/or group psychotherapy with schizophrenics. Bis. Nerv. Syst. 25:77.Google Scholar
  11. Green, D. E., and Forrest, I. S. 1966. In vivo metabolism of chlor-promazine. Canad. Psychiat. Assoc. J. 11:299.Google Scholar
  12. Grinspoon, L.; Ewalt, J. R.; and Shader, R. 1967. Long-term treatment of chronic schizophrenia. Int. J. Psychiat. 4:116.Google Scholar
  13. Hollister, L. E.; Overall, J. E.; Bennett, J. L.; Kimbell, I., Jr.; and Shelton, J. 1967. Specific therapeutic actions of aceto-phenazine, Perphenazine and benzquinamide in newly admitted schizophrenic patients. Clin. Pharmacol. Ther. 8:249.PubMedGoogle Scholar
  14. Hollister, L. E.; Curry, S. H.; Derr, J. E.; and Kanter, S. L. 1970. Studies of delayed-action medication. V.-Plasma levels and urinary excretion of four different forms of chlorpromazine. Clin. Pharmacol. Ther. 11:49.PubMedGoogle Scholar
  15. Hordern, A. 1961. Medical Progress. Psychiatry and the tranquil-izers. New Eng. J. Med. 265:585.Google Scholar
  16. Janssen, P. A. J. 1970. Chemical and pharmacological classification of neuroleptics. In Modern Problems of Pharmacoipsychiatry3 vol. 5. The Neuroleptics. D. P. Bobon, P. A. J. Janssen, and J. Bobon (eds.). Basel: S. Karger, p. 33.Google Scholar
  17. Kinross-Wright, J. 1967. The current status of phenothiazines. J.A.M.A. 200:461.PubMedCrossRefGoogle Scholar
  18. Klett, C. J., and Moseley, E. C. 1965. The right drug for the right patient. J. Consult. Clin. Psychol. 29:546.Google Scholar
  19. Kurland, A. A.; Hanlon, T. E.; Tatom, M. H.; and Michaux, M. H. 1961. The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. J. Nerv. Ment. Dis. 133:1.PubMedCrossRefGoogle Scholar
  20. Lasky, J. J.; Klett, C. J.; Caffey, E. M., Jr.; Bennett, J. L.; Rosenblum, M. P.; and Hollister, L. E. 1962. Drug treatment of schizophrenic patients: a comparative evaluation of chlorpromazine, chlorprothixene, fluphenazine, reserpine, thioridazine, and triflupromazine. Dis. Nerv. Syst. 23:698.Google Scholar
  21. Michaux, M. H.; Hanlon, T. E.; Ota, K. Y.; and Kurland, A. A. 1964. Phenothiazines in the treatment of newly admitted state hospital patients: global comparison of eight compounds in terms of an outcome index. Curr. Ther. Res. 6:331.PubMedGoogle Scholar
  22. National Institute of Mental Health, Psychopharmacological Service Center Collaborative Study Group 1964. Phenothiazine treatment in acute schizophrenia. Arch. Gen. Psychiat. 10:246.CrossRefGoogle Scholar
  23. National Institute of Mental Health and Psychopharmacology Research Branch Collaborative Study Group 1967. Differences in clinical effects of three phenothiazines in “acute” schizophrenia. Dis. Nerv. Syst. 28:369.Google Scholar
  24. Overall, J. E.; Hollister, L. E.; Honigfeld, G.; Kimbell, I. H., Jr.; Myer, F.; Bennett, J. L.; and Caffey, E., Jr. 1963. Comparison of acetophenazine with Perphenazine in schizophrenics: demonstration of differential effects based on computer-derived diagnostic models. Clin. Pharmacol. Ther. 4:200.Google Scholar
  25. Platz, A. R.; Klett, C. J.; and Caffey, E. M., Jr. 1967. Selective drug action related to chronic schizophrenic subtype (a comparative study of carphenazine, chlorpromazine and trifluoperazine). Dis. Nerv. Syst. 28:601.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1971

Authors and Affiliations

  • Leo E. Hollister
    • 1
    • 2
  1. 1.Veterans Administration HospitalPalo AltoUSA
  2. 2.Stanford University School of MedicineStanfordUSA

Personalised recommendations